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A general expression vector (pMB332) for the fission yeast Schizosuccharomyces pombe was constructed. The heterolo- 
gous gene expression is driven by the S. pombe alcohol dehydrogenase (adh) promoter. Transcription termination signals 
were isolated from the S. pombe actin gene. The vectors carry the Succharomyces cerevisiue Uru.? gene, which comple- 
ments the S. pombe urul mutation. The plasmid stability is conferred by the S. pombe ars and stb elements isolated from 
pFL120 [(1983) Cell 32, 371-3771. An ‘ATG’ vector (pMB340) was created, which allows the expression of protein frag- 
ments fused to a translational start codon downstream of the adh promoter. The function of this vector system is shown 
by the production of the human blood coagulation protein factor XIIIa. 
Expression vector; Alcohol dehydrogenase; Gene promoter; Fission yeast; Factor XIIIa; (Schizosuccharomyces pombe, Human) 
1. INTRODUCTION 
The baker yeast Saccharomyces cerevisiae has 
gained popularity as a host for heterologous pro- 
tein synthesis. This is due to the fact that Sac. 
cerevisiae is not a pathogen and is widely accep- 
table for use in the food industry. In addition, 
yeast exhibits the posttranslational modification 
systems (glycosylation, acetylation, phosphoryla- 
tion etc.) which are lacking in prokaryotic 
microorganisms. The ability to introduce foreign 
DNA into the yeast cell and into the yeast genome, 
coupled with advantages in molecular cloning 
techniques has led to a number of eukaryotic pro- 
teins expressed in Sac. cerevisiae. 
Among the yeast species studied so far, the fis- 
sion yeast Schizosaccharomyces pombe, which is 
taxonomically and evolutionarily far distant from 
the baker yeast [ 11, has received less attention con- 
cerning genetic engineering. S. pombe probably 
provides an alternative host for heterologous gene 
expression. As Sac. cerevisiae, the fission yeast is 
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also nonpathogenic and is genetically and 
physiologically well characterized (for review see 
[2,3]). The fission yeast has found interest in the 
alcohol industry [4] and is used as a means of 
deacidification of grape musts, because this yeast 
can metabolize malic acid [5,6]. 
So far, there are only some examples for expres- 
sion of heterologous genes from higher eukaryotes 
in S. pombe: the polyoma virus middle-T antigen 
[7], the human antithrombin III [8] and the human 
liver epoxide hydrolase [9]. When promoters from 
Sac. cerevisiae genes were used [7,8], the expres- 
sion rate was rather low, because transcription in- 
itiation signals recognized by S. pombe and Sac. 
cerevisiae are not identical [lO,ll]. The only 
reported homologous promoter for expression 
studies in S. pombe is the element from the alcohol 
dehydrogenase gene (adh), which has been cloned 
and sequenced by Russell and Hall [ 121. For 
mitotic stability and partitioning of plasmids in the 
fission yeast, a DNA sequence termed stb [ 131 is 
needed in addition to an S. pombe ars element. So 
far, no expression vector for S. pombe is available, 
which combines (i) homologous transcription in- 
itiation and (ii) termination signals in combination 
with (iii) selection markers for E. co/i and S. 
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pombe in addition to (iv) DNA elements which 
function as ori and (v) elements which improve the 
symmetric segregation of the plasmid. This paper 
describes the construction of general expression 
vectors for S. pombe and its use to produce en- 
zymatically active human blood coagulation pro- 
tein factor XIIIa (FXIIIa). 
2. MATERIALS AND METHODS 
2.1. Microbial strains and methods 
E. coli DHl [14] was used for cloning in bacteria and cloning 
and expression in yeast was done in S. pombe 972 h-ura4-294 
[13]. Transformed yeast cells were grown at 30°C in a shaker 
flask in selective YNBA medium (0.67% yeast nitrogen base 
without amino acids, 2% dextrose, 0.2% asparagine). After 
two days, complex medium YPD (1% yeast extract, 2% pep- 
tone, 2% dextrose) was inoculated with 10% of a preculture 
grown in YNBA medium. Yeast cell extracts were prepared in 
a glass bead mill. 
2.2. DNA methods 
Isolation of plasmid DNA, preparation of DNA fragments, 
DNA synthesis reactions, DNA ligations, transformation in E. 
co/i and screening of plasmid containing colonies were carried 
out essentially as described by Maniatis et al. [lS]. Transforma- 
tion of S. pombe was done as described previously [16]. 
Nucleotide sequence was determined by the dideoxy method 
[17] using [3SS]dATPcuS. 
2.3. Protein analysis 
FXIIIa concentration was measured by an ELISA. Microtiter 
plates were coated with anti-FXIIIa immunoglobulins isolated 
from sera of rabbits immunized with human FXIlIa of 99% 
purity. Peroxidase-coupled anti-FXIIIa antibodies were used as 
conjugate. Western blots were done according to Burnette [18] 
using anti-FXlIIa rabbit serum and a second antibody coupled 
with alkaline phosphatase. Activity of FXIIIa was measured by 
the clot stability assay [19]. 
3. RESULTS 
3.1. Construction of an S. pombe expression 
vector 
The strategy to construct efficient expression 
vectors for the fission yeast was to combine 
characterized transcription and termination signals 
of S. pombe genes with elements that facilitate a 
high plasmid stability in this yeast. The ancestor 
for the promoter was the vector pEVPl1 [20]. This 
plasmid is based on the Sac. cerevisiae-E. coli shut- 
tle vector YEpl3 [21] in which has been inserted 
the 700 bp EcoRI/SpH fragment containing the S. 
pombe adh promoter adjacent to the EcoRI/Hin- 
dII1 polylinker from pUC12. The EcoRI site is at 
position -45 to the translational start codon of 
the adh gene. The adh promoter fragment was 
isolated from pEVPl1 and was ligated into the 
plasmid backbone of pFL20, from which the 
region which confers tetracycline resistance in E. 
coli has been deleted (for details see fig.1). The 
BamHI/PvuII DNA fragment from pFL20 confers 
the ars activity in S. pombe and the stb element 
promotes the mitotic stability of the vector in the 
fission yeast. In addition, this DNA fragment car- 
ries the ori and the ampR gene for selection in E. 
co/i. Downstream of the adh promoter within 
pMB229, we inserted a DNA fragment from 
plasmid pSPA2 that carries efficient transcription 
termination signals originating from the S. pombe 
actin gene [22]. The BamHI site is located in the 
carboxy-terminal region 96 bp upstream of the 
translational stop codon of the actin coding DNA. 
The transcription terminates at position + 59/+ 60 
downstream of the protein coding sequence of the 
actin gene. 
The new S. pombe/E. coli shuttle vector 
pMB332 has the following features: (i) due to the 
S. pombe ars and stb elements, it replicates 
episomally and has a high mitotic stability; (ii) the 
Sac. cerevisiae Ura3 gene can complement S. 
pombe Ural strains to uracil prototrophy; (iii) it 
carries the strong transcription initiation signals 
from the S. pombe adh gene; and (iv) the transcrip- 
tion termination signals from the S. pombe actin 
gene. (v) The unique BamHI site between the pro- 
moter and terminator elements can be used for in- 
sertion of foreign genes. The unique BamHI site is 
25 bp downstream of the transcription initiation 
site. A transcriptional hybrid would be synthesiz- 
ed, which has an adh specific leader of 13 bases, a 
Fig.1. Genealogy of the S. pombe expression vector pMB332. For detailed cloning procedure and function of the various elements 
see text. At the bottom, the relevant DNA sequence around the unique BamHI cloning site between the fusion of the adh promoter 
and actin terminator is shown. Restriction enzymes within the brackets indicate the fusion of two different DNA ends. The Nhel site 
in pMB332 is regenerated by fusion to the HaeIII site. The open arrow indicates the transcription start point within the adh gene, 
the two thin arrows indicate the transcription termination within the actin gene. A possible polyadenylation signal sequence is indicated 
by a broken line. 
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short sequence determined by the 
SstI/SmaI/BumHI DNA linker region and 
possibly stretches of the foreign mRNA leader. 
The transcription termination signals of the actin 
gene are located 154 bp 3 ’ to the unique BamHI 
site. In case that the foreign gene carries no signals 
for transcription termination in the fission yeast, 
the 3 ‘-nontranslated region of the expressed 
mRNA thus would additionally contain a stretch 
of 96 bases determined by the carboxy-terminal 
portion of the actin coding DNA and the adjacent 
sequence of the nontranslated actin mRNA 
stretch. (vi) A further advantage of pMB332 is its 
relatively small size compared to other yeast clon- 
ing vectors. 
3.2. Construction of an S. pombe 'A TG vector’ 
In order to facilitate the expression of foreign 
DNA sequences coding for protein fragments, but 
missing a translational start codon, we broadened 
pMB332 to an ‘ATG vector’. The plasmid was 
opened with BarnHI, the single-stranded 
overhangs were digested with nuclease SI and a 
synthetic DNA linker was inserted such that a 
translational start codon is located 31 bp 
downstream of the adh transcription initiation site. 
For translational in frame fusion of foreign DNA, 
one can either use the first BarnHI site or the uni- 
que BgflI site which follow the ATG codon. Many 
eukaryotic proteins are subjected to a variety of 
co- or posttranslational modifications. The struc- 
tural alterations resulting from these modifications 
can influence translocation, biological activity or 
turnover. Two enzymes, methionine aminopep- 
tidase and W-acetyltransferase can act in concert 
to remove the initiator methionine residue and add 
an N-acetyl group [23]. Several lines of evidence 
suggest hat the N-terminal amino acid of proteins 
may play a major role in determining intracellular 
stability, which led to the N-end rule [24]. Serine in 
position +2 can cause a high stability of in- 
tracellular proteins. In addition, a compilation of 
the distribution of amino acids at position +2 
showed, that in total, 28% of baker yeast genes 
favor serine at this position [25]. Therefore we 
positioned a triplet coding for serine at position 
+2 sandwiched between the translational start 
codon and the cloning sites. Once the foreign DNA 
has been inserted into the BamHI or BgflI site, it 
can be isolated in its modified form with its 
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Fig.2. Relevant DNA sequence of the ‘ATG vector’ pMB340. 
The translational ATG start codon and the possible BumHI and 
BgflI cloning sites for translational in frame fusion are marked 
in bold letters. 
translational start codon on a transportable DraI 
fragment and can be transferred to other expres- 
sion vectors. 
3.3. Expression of human FXIIIa in S. pombe 
The function of the expression vector was 
analyzed by cloning a prokaryotic and an 
eukaryotic test gene into the plasmid pMB332. 
The prokaryotic marker gene was the E. coli 
IacZ gene, coding for ,&galactosidase. S. pombe 
cells were transformed with pMB333, a modified 
pMB332, in which the 3000 bp HindIII/NcoI IacZ 
bearing DNA fragment from pLG400 [26] had 
been cloned. These cells produced enzymatically 
active ,&galactosidase. Colonies turned blue on 
agar plates containing the enzyme substrate X-Gal 
and cell free extracts hydrolyzed the substrate 
ONPG (data not shown). 
For more detailed analysis, we tested the new ex- 
pression system to direct the synthesis of the 
human protein factor XIIIa (FXIIIa). FXIIIa is a 
blood coagulation protein that is distributed in 
plasma, platelets and placenta. The plasma protein 
consists of a tetramer (azbz) containing two copies 
of each an a and b subunit, while the platelet and 
the placenta-derived material is an a2 dimer [27]. 
The a subunit contains the active sites. FXIIIa 
(84 kDa) is activated by thrombin to FXIIIa’ to 
yield the enzymatically active transglutaminase 
(80 kDa) and the activation peptide of 4 kDa from 
the amino-terminus (for enzymatic and clinical 
aspects see review [28]). The cDNA coding for 
FXIIIa has been cloned and sequenced [29] and 
FXIIIa has been recently expressed in E. coli 
[30,31]. But most of the material is found in un- 
soluble inclusion bodies and therefore has no 
biological activity. 
To express FXIIIa in S. pombe, we ligated the 
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Fig.3. Western blot analysis of S. pombe cell extracts with anti- 
FXIIIa serum. S. pombe [pMB334] cells expressing FXIIIa and 
harvested after 70 h growing in complex medium (lane 1) and 
after 90 h (lane 2); purified placental FXIIIa (lane 3); extract of 
S. pombe cells without plasmid; molecular mass marker 
proteins (lane M): only /3-galactosidase (116 kDa) and 
phosphorylase (97 kDa) can be identified in the original blot 
due to a faint unspecific immunoreaction. 
2327 bp EcoRI/HindIII fragment from pTrc99A- 
FXIIIa [31] into the unique BarnHI site of 
pMB332. The resulting plasmid pMB334 was 
transformed into S. pombe Ural strains, and uracil 
prototrophic colonies were analyzed for synthesis 
of FXIIIa. In extracts of S. pombe [pMB334] cells, 
grown in complex YPD medium, up to 2 mg 
FXIIIa/l culture broth were detected by a specific 
ELISA. Western blot analyses show that FXIIIa 
synthesized in S. pombe has the same apparent 
molecular mass as placenta-derived FXIIIa and no 
degradation products of recombinant FXIIIa 
could be identified (fig.3). The biological activity 
of recombinant FXIIIa from the fission yeast was 
verified in the clot stability assay. 
4. DISCUSSION 
Here we present new expression vectors for the 
fission yeast S. pombe, which allow the construc- 
tion of transcriptional or translational fusions. To 
facilitate effective production rates, homologous 
signals for initiation and termination of transcrip- 
tion were combined with elements that confer a 
high mitotic stability of the vectors. The produc- 
tion yield of the human placenta protein was 
2 mg/l, when the transformants were grown in 
shaker flasks. Even higher yields should be obtain- 
ed under optimized conditions in fed batch 
fermentations. It seems likely that several factors 
are responsible for the yield of heterologous pro- 
ducts. These could be the stability of the protein, 
the efficiency of translation of the heterologous 
mRNA, the stability of the transcripts and the effi- 
ciency of the mRNA synthesis as well as the copy 
number of the expression vector [32]. Therefore, 
the production yield will differ from one case to 
the next and the expression efficacy has to be in- 
dividually tested for each protein. 
So far, FXIIIa is stably expressed in S. pombe, 
has the same molecular mass and can be converted 
to enzymatically active FXIIIa’ by the action of 
thrombin. Deduced from the cDNA sequence (291, 
FXIIIa has six potential glycosylation sites, but no 
sugar residues were detected when the protein se- 
quence was analyzed [33]. As the migration pattern 
of FXIIIa from yeast is identical to FXIIIa from 
placenta, we conclude that the recombinant 
FXIIIa is not glycosylated or it contains only 
minor carbohydrate residues. 
Based on the expression system described above, 
S. pombe might be an appropriate and alternative 
host for production and functional analysis of 
complex eukaryotic foreign proteins. 
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